Cargando…
Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis
BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891920/ https://www.ncbi.nlm.nih.gov/pubmed/27255888 http://dx.doi.org/10.1186/s13075-016-1031-0 |
_version_ | 1782435349073494016 |
---|---|
author | Johansson, Linda Pratesi, Federico Brink, Mikael Ärlestig, Lisbeth D’Amato, Claudia Bartaloni, Debora Migliorini, Paola Rantapää-Dahlqvist, Solbritt |
author_facet | Johansson, Linda Pratesi, Federico Brink, Mikael Ärlestig, Lisbeth D’Amato, Claudia Bartaloni, Debora Migliorini, Paola Rantapää-Dahlqvist, Solbritt |
author_sort | Johansson, Linda |
collection | PubMed |
description | BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. METHODS: A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). RESULTS: In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401 in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide polymorphisms (SNPs) were significantly associated with anti-HCP1. CONCLUSIONS: Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1031-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4891920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48919202016-06-04 Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis Johansson, Linda Pratesi, Federico Brink, Mikael Ärlestig, Lisbeth D’Amato, Claudia Bartaloni, Debora Migliorini, Paola Rantapää-Dahlqvist, Solbritt Arthritis Res Ther Research Article BACKGROUND: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. METHODS: A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). RESULTS: In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401 in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide polymorphisms (SNPs) were significantly associated with anti-HCP1. CONCLUSIONS: Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1031-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-03 2016 /pmc/articles/PMC4891920/ /pubmed/27255888 http://dx.doi.org/10.1186/s13075-016-1031-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Johansson, Linda Pratesi, Federico Brink, Mikael Ärlestig, Lisbeth D’Amato, Claudia Bartaloni, Debora Migliorini, Paola Rantapää-Dahlqvist, Solbritt Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title | Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title_full | Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title_fullStr | Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title_full_unstemmed | Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title_short | Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
title_sort | antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891920/ https://www.ncbi.nlm.nih.gov/pubmed/27255888 http://dx.doi.org/10.1186/s13075-016-1031-0 |
work_keys_str_mv | AT johanssonlinda antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT pratesifederico antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT brinkmikael antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT arlestiglisbeth antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT damatoclaudia antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT bartalonidebora antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT migliorinipaola antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis AT rantapaadahlqvistsolbritt antibodiesdirectedagainstendogenousandexogenouscitrullinatedantigenspredatetheonsetofrheumatoidarthritis |